Human heart cells are altered by spaceflight, but return mostly to normal on Earth – Space Daily

Heart muscle cells derived from stem cells show remarkable adaptability to their environment during and after spaceflight, according to a study publishing November 7 in the journal Stem Cell Reports.

The researchers examined cell-level cardiac function and gene expression in human heart cells cultured aboard the International Space Station for 5.5 weeks. Exposure to microgravity altered the expression of thousands of genes, but largely normal patterns of gene expression reappeared within 10 days after returning to Earth.

"Our study is novel because it is the first to use human induced pluripotent stem cells to study the effects of spaceflight on human heart function," says senior study author Joseph C. Wu of Stanford University School of Medicine.

"Microgravity is an environment that is not very well understood, in terms of its overall effect on the human body, and studies like this could help shed light on how the cells of the body behave in space, especially as the world embarks on more and longer space missions such as going to the moon and Mars."

Past studies have shown that spaceflight induces physiological changes in cardiac function, including reduced heart rate, lowered arterial pressure, and increased cardiac output. But to date, most cardiovascular microgravity physiology studies have been conducted either in non-human models or at tissue, organ, or systemic levels. Relatively little is known about the role of microgravity in influencing human cardiac function at the cellular level.

To address this question, Wu and his collaborators (including graduate student Alexa Wnorowski, former Stanford graduate student Arun Sharma, now a research fellow at Cedars-Sinai in Los Angeles, and former Stanford graduate student turned astronaut Kathleen Rubins) studied human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). They generated hiPSC lines from three individuals by reprogramming blood cells, and then differentiated them into hiPSC-CMs.

Beating hiPSC-CMs were then launched to the International Space Station aboard a SpaceX spacecraft as part of a commercial resupply service mission. Simultaneously, ground control hiPSC-CMs were cultured on Earth for comparison purposes.

Upon return to Earth, space-flown hiPSC-CMs showed normal structure and morphology. However, they did adapt by modifying their beating pattern and calcium recycling patterns.

In addition, the researchers performed RNA sequencing of hiPSC-CMs harvested at 4.5 weeks aboard the International Space Station, and 10 days after returning to Earth. These results showed that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples.

Most notably, gene pathways related to mitochondrial function were expressed more in space-flown hiPSC-CMs. A comparison of the samples revealed that hiPSC-CMs adopt a unique gene expression pattern during spaceflight, which reverts to one that is similar to groundside controls upon return to normal gravity.

"We're surprised about how quickly human heart muscle cells are able to adapt to the environment in which they are placed, including microgravity," Wu says. "These studies may provide insight into cellular mechanisms that could benefit astronaut health during long-duration spaceflight, or potentially lay the foundation for new insights into improving heart health on Earth."

According to Wu, limitations of the study include its short duration and the use of 2D cell culture. In future studies, the researchers plan to examine the effects of spaceflight and microgravity using more physiologically relevant hiPSC-derived 3D heart tissues with various cell types, including blood vessel cells. "We also plan to test different treatments on the human heart cells to determine if we can prevent some of the changes the heart cells undergo during spaceflight," Wu says.

Research Report: "Effects of Spaceflight on Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Structure and Function"

Related LinksCell PressSpace Medicine Technology and Systems

With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords.

Our news coverage takes time and effort to publish 365 days a year.

If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.

See the rest here:
Human heart cells are altered by spaceflight, but return mostly to normal on Earth - Space Daily

Jennifer OConnell: President Kanye in 2024? Be very afraid America – The Irish Times

I realised I was listening to one of the most important cultural messages we need at this moment in American history. Kanyes counter-cultural voice is desperately needed, goes one rapturous review of Kanye Wests new album, Jesus is King.

Every second I spend listening to it, my mind is focused on the Holy One. I see Jesus glorified throughout every track.

That second line is a clue that the review didnt come from Rolling Stone or NME. Instead, it emerged on that somewhat less well-known rap-lovers bible, the website of the organisation Concerned Women for America.

As its name might hint, this is an evangelical Christian non-profit, normally associated with its stands against feminism, same-sex marriage, stem cell research, pornography, cloning, gambling, sex education and sure, why not while theyre at it evolution. And now its reviews of rap albums.

The reinvention of Kanye West rapper, tweet-happy pseudo-philosopher, purveyor of such wisdoms as slavery is a choice, husband of a Kardashian, and more recently, icon of the alt-right is complete. He has stopped hinting that he might run for president of the United States in 2024 (in January this year, he tweeted simply 2024), and has started just declaring it outright.

There will be a time when I will be the president of the US, he confidently predicted in an interview with an Apple Music show, Beats 1, while sitting overlooking his private lake surrounded by a herd of gambolling deers on his multithousand acre property in Wyoming. He also reveals in the interview that he didnt like the property when he first saw it, but then noticed that it matched his colour palette. I was like, these are the Yeezy tones right here, Yeezy being the brand of 300 footwear he flogs with Adidas. The right to own land matching your expensive runners could make for a compelling election promise.

So Kanye 2024 is happening. And why not? If property salesman, charmless reality TV star, unhinged tweeter, reader of no books without his name in the title, malignant narcissist and performative misogynist Donald Trump can do it, why not rapper and shoe salesman, husband of a reality TV star, unhinged tweeter, reader of no books without his name in the title, malignant narcissist and performative misogynist Kanye West?

Well, lets see. Kanye might be the darling of everyone from Conservative Women for American to Donald Trump jnr (who tweeted that he was the epitome of fearless creativity and dangerous, unapprovedideas), but there is the question of his not exactly on-brand past his porn addiction, his sex addiction, his opioid addiction, his liking for the word bitch. If his newfound fanbase appears surprisingly untroubled by all of this, its because they are able to suggest it was all just a scene-setting prelude to his current, more wholesome incarnation.

And he has been obliging them with plenty of evidence of this reinvention. He recently said he tried to ban premarital sex among people working on the album. He also denounced abortion and the morning-after pill, accused Democrats of brainwashing black people, and said that God had given him a $68 million tax refund. Its astonishing how many extremely rich people subscribe to the belief that the richer you are, the more God loves you. Or perhaps its not astonishing at all.

Kanye pretended to be who he wasnt to show you who he really is, explains Mike Cernovich, the alt-right, anti-feminist conspiracy theorist, predicting that Kanye could bring the races together.

The idea of the rapper putting himself forward for nomination seems ridiculous, surreal, daft and, simultaneously, sort of inevitable. What could be a more natural conclusion to a decade in which the global news agenda dissolved into a dark, Dadaist comedy, a time when charlatan/joker/narcissist/no political experience or identifiable policies whatsoever became part of the job description for any sort of serious run at high-profile high office?

Troublingly, the mainstream US media is falling into exactly the same trap with West that it fell into with Trump. Its alternately ignoring him, and treating him like the punchline to a grim, postmodern joke, while clinging to the hope that something shiny will come along before 2024 to distract him before the country embarrasses itself any further. Because nobody is actually all that sure America will be ready to put a grown-up in charge by then.

Is this all just a publicity stunt for Kanye? I wouldnt count on it, any more than it was all just a publicity stunt for Trump. As in: it may just be a publicity stunt, but that doesnt mean it wont happen anyway.

On the subject of his own greatness, unlimited messianic potential and his belief in the direct line his creator has to his bank balance, Kanye is deadly serious. With his pseudo-philosophical, self-help musings; his disregard for facts, history or science; his love of conspiracy theories; his paranoia; his parasitic relationship with the media and the astonishing depths of his own self-belief, its hard to imagine, in fact, a more appropriate emblem for this age were in. I suspect his ambitions dont stop at being the next Donald Trump. He fancies himself as the next Jesus Christ.

joconnell@irishtimes.com

See the article here:
Jennifer OConnell: President Kanye in 2024? Be very afraid America - The Irish Times

Global Animal Stem Cell Therapy Market – Industry Outlook and Forecast 2019-2024 – Real Viewpoint

The Animal Stem Cell Therapy market report provides an unbiased and detailed analysis of the on-going trends, opportunities/ high growth areas, market drivers, which would help stakeholders to device and align market strategies according to the current and future market dynamics. The Animal Stem Cell Therapy market report thoroughly covers the market by product device, deployment, verticals and countries.

Look insights of Global Animal Stem Cell Therapyindustry market research report athttps://www.pioneerreports.com/report/619244

About Animal Stem Cell Therapy Industry

The overviews, SWOT analysis and strategies of each vendor in the Animal Stem Cell Therapy market provide understanding about the market forces and how those can be exploited to create future opportunities.

Key Players in this Animal Stem Cell Therapy market are:

Get sample Copy of this Animal Stem Cell Therapy Market Report athttps://www.pioneerreports.com/request-sample/619244

Important application areas of Animal Stem Cell Therapy are also assessed on the basis of their performance. Market predictions along with the statistical nuances presented in the report render an insightful view of the Animal Stem Cell Therapy market. The market study on Global Animal Stem Cell Therapy Market 2018 report studies present as well as future aspects of the Animal Stem Cell Therapy Market primarily based upon factors on which the companies participate in the market growth, key trends and segmentation analysis.

Product Segment Analysis of the Animal Stem Cell Therapy Market is:

Industry SegmentationVeterinary HospitalsResearch Organizations

Channel (Direct Sales, Distributor) Segmentation

Look into Table of Content of Animal Stem Cell Therapy Market Report at https://www.pioneerreports.com/TOC/619244

The scope of Animal Stem Cell Therapy Market report:

Global market size, supply, demand, consumption, price, import, export, macroeconomic analysis, type and application segment information by region, including:Global(Asia-Pacific [China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East & Africa[GCC, North Africa, South Africa],

South America[Brazil, Argentina, Columbia, Chile, Peru])

Industry chain analysis, raw material and end users information

Global key players information including SWOT analysis, companys financial figures, Laser Marking Machine figures of each company are covered.

Powerful market analysis tools used in the report include: Porters five forces analysis, PEST analysis, drivers and restraints, opportunities and threatens.

Based year in this report is 2019; the historical data is from 2014 to 2018 and forecast year is from 2020 to 2024.

Inquire for further detailed information of Animal Stem Cell Therapy Market Report at:https://www.pioneerreports.com/pre-order/619244

Table Content of Animal Stem Cell Therapy Market Research Report

In this study, the years considered to estimate the market size ofAnimal Stem Cell Therapy Market are as follows:-

No Of Pages in Animal Stem Cell Therapy Market Report: 125

Single User Licence Price: USD 2350

Purchase report athttps://www.pioneerreports.com/checkout/619244

Here is the original post:
Global Animal Stem Cell Therapy Market - Industry Outlook and Forecast 2019-2024 - Real Viewpoint

VIDEO: Cancer survivor meets the donor who saved his life at a runDisney event – Inside the Magic

Get the tissues ready- for two runDisney participants this years Disney Wine & Dine Half Marathon culminated with an outpouring of gratitude and emotions.

Boyd Dunleavy is a Canadian runner who was diagnosed with acute myeloid leukemia, a rare blood cancer, in 2011. Dunleavys doctors estimated that he would have about a 10% chance of living more than just a few months if his medical team was unable to find a matching stem cell transplant donor outside of his family. Miraculously, after various treatments and a cancer relapse in 2012, Dunleavys doctors found a match- Nathan Barnes.

When Barnes was identified as a match, he was stationed in Japan as a gunners mate in the US Navy, but he was still able to donate the stem cells that would ultimately save Dunleavys life. Dunleavy was awestruck upon learning that a match had been found and that his donors name was Nathan: When we found out it was a gentleman named Nathan, it was incredible, he said, Our middle sons name is Nathan, and it means Gift of God.'

While recovering from the transplant procedure, Dunleavy began to use running as a recovery aid, which quickly turned into a passion. Since his transplant, hes become an active participant in runDisney events having completed two marathons, multiple virtual races, four half marathons, and a few 10K races.

Dunleavy ran in this years Disney Wine & Dine Half Marathon, and after seven years of being stationed overseas, Barnes was able to attend the race and finally meet Dunleavy and his family. Barnes met Dunleavy at the finish line of this years race to award him his medal.

My motto is never lose hope,' explains Dunleavy, Life is a special gift. We were told that with the stem cell transplant, my chances of living five years were only 30 percent. This is Year 7! Never lose hope.

Source: Disney

The rest is here:
VIDEO: Cancer survivor meets the donor who saved his life at a runDisney event - Inside the Magic

Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem – Benzinga

Global Regenerative Group, a proven company in the field of medicine and innovation, is pleased to announce partnerships with Remodem and Aurafix.

Boca Raton, FL, November 09, 2019 --(PR.com)-- Remodem is a company offering an innovative product with an interesting mechanism of action.

A new molecule, external inorganic gel liquid magnet, has been developed using a combination of silica, calcium chloride, and tetrahydropiperine, which have a very high water holding capacity. External inorganic gel liquid magnet is a new generation, patented molecular structure with a high hydrophilic feature that is not likely to be absorbed into the skin.

It is applied as a layer with a minimum thickness of 3mm to cover the entire edema area that occurs after tissue trauma. The area of application is then covered with sterile bandage for twelve hours.

This unique product, Remodem Superficial Swelling Reducing Gel, helps to reduce swelling and discoloration that occur due to sprain, muscle strain, trauma, sports injury, as well as aesthetic and plastic surgeries. As Remodem is used in many fields of medicine, this partnership will bring the Remodem product line to GRGs network of professionals around the world and allow the company to reach its full potential.

With its beginnings in a small workshop, Aurafix has continually improved itself by paying attention to the importance of quality, workmanship, and superior service as well as investing in human capital and technology. Aurafix has been an application center in the fields of orthesis, prosthesis and rehabilitation since 2002.

The Aurafix products are focused in three areas: Orthopedics, Liposuction, and Compression. All of the products manufactured are flawlessly delivered to users using a strict quality control process that ensures accordance with the relevant standards:

- Adhesive VELCRO surfaces provide comfort and ease of use.- Flexible neoprene material provides ease of movement and a warming, soothing effect along with high strength. Increased body temperature accelerates the healing process by increasing blood circulation.-A flexible cotton fabric with high air permeability. The flexible structure provides the required support and comfort by wrapping the body.

The company continues to grow and operate as a leading brand name in the domestic market. By partnering with Global Regenerative Group, Aurafix will become a worldwide recognized brand.

Aurafix offers 240 different Orthopedic products, 50 Liposuction, and 50 Compression products.

For full product list please see the catalogues:

- Aurafix Orthopedics- Aurafix Liposuction- Aurafix Compression

Of the agreement, the President of Global Regenerative Group, Randolph Beimel said, The Global Regenerative Group is a medical community comprised of doctors, scientists, hospital administrators, businessmen, and entrepreneurs in more than 35 countries; all focused on developing the newest and most innovative products to provide the best possible outcomes for the patient. The GRG relationships around the world give us the opportunity to identify the highest quality products in a particular country and distribute them globally. The international launch of the Aurafix and Remodem product lines will offer patients on four continents the same benefits that patients in Turkey have experienced for many years.

Global Regenerative Group is a fast-growing company, collaborating with specialists and clinics around the world, with the primary purpose of delivering innovative medical care to the patient. During the last decade the company has developed extensive experience in the most advanced medical device industries. Recently, the company's emphasis has been focused exclusively on Regenerative Medicine, such as stem cell technologies, products, and therapies.

Global Regenerative Trade, a subsidiary of Global Regenerative Group, is dedicated to bringing science in practice through product development. Our main mission is supporting and accelerating the healing process following medical treatment by enhancing the bodys own capabilities. Global Regenerative Trade serves as a hub, bringing together products used in various fields of medicine. Using cumulative knowledge and expertise in the field of Regenerative medicine, we develop products which enhance the quality of life of patients and are more user-friendly for doctors.

Contact Information:Global Regenerative GroupRandy Beimel954-778-2581Contact via Emailglobalregenerative.group

Read the full story here: https://www.pr.com/press-release/798942

Press Release Distributed by PR.com

Link:
Global Regenerative Group Enters Into Distribution Partnership with Aurafix & Remodem - Benzinga

Can mfines Hospital Network Bridge The Gaps In Indias Healthcare Delivery Systems – Inc42 Media

mfine enables patients to get doctor consultations virtually through its app interface

It claims to have touched 2,75,000 patients, handling an average of 1.5K consultations per day

The IBEF has estimated the Indian healthcare market to be valued at $372Bn by 2022

The healthcare industry in India is said to be one of the fastest growing sectors backed by Indias rising income, health awareness, and access to insurance, but also due to the increase in lifestyle and stress-related diseases. The IBEF has estimated the Indian healthcare market to be valued at $372Bn by 2022.

In India, the doctor to patient ratio in the allopathy sector stands at 1:1596 (far lower than the 1:1400 WHO standard) and the country is ranked 145 among 195 countries on the healthcare index.

Tapping the urgent need for improved healthcare data and quality access to doctors, telemedicine startups have sprouted in many cities in India. Telemedicine startups essentially help patients get doctor consultations virtually through apps or web-based videos, chats and voice guidance.

According to a Mckinsey report, India could save up to $10 Bn in 2025, by using telemedicine instead of in-person doctor consultations.

While, Practo has definitely become the most recognised player in the telemedicine space. Companies such as Lybrate, DocsApp, Medcords and mfine are also attempting to solve Indias healthcare problem in their own distinct ways.

One of the major challenges in telemedicine has been the process of onboarding doctors and building patients trust in digital consultations. mfine approaches this problem through hospital collaborations which help the company to ensure the quality of doctors, get access to a wide range of services and also drive patients trust because of the hospitals brand recognition, cofounder of mfine, Ashutosh Lawania told Inc42.

Bengaluru-based was founded in 2017 by former Myntra executives Lawania and Prasad Kompalli and later joined by Ajit Narayanan and Arjun Chaudhary. It counts SBI Holdings, SBI Ven Capital, Prime Venture Partners, BEENEXT, Stellaris Venture Partners, Alteria Capital and Mayur Abhaya CEO of stem cell banking company LifeCell, as its investors. It has raised a total of $22.9 Mn across three funding rounds.

mfine is focused on onboarding private hospitals within the range of 50 to 1000 beds.The company majorly wants to target 7000-8000 large hospitals which have pan-India presence, and offers all kinds of specialities and facilities.

mfine currently has over 200 hospitals and 750 plus doctors across six cities including Hyderabad, Delhi, Bengaluru, Pune, Mumbai and Kolkata. Some of the notable partners include Sunshine, Apollo Bangalore, Cloudnine, KIMS Hyderabad, Fortis Mumbai and Sarvodaya among others. In the past 12 months, mfine claims to have touched 2,75,000 patients, handling an average of 1.5K consultations per day.

The company operates on a B2C model, on every new lead generated whether online consultation or physical visit at the hospital, the company takes certain commission and a part of it is shared with the partner hospital. This means hospitals are incentivised to tie-up since it increases their patient inflow and also lets more people access its services, who would have otherwise not approached the hospital.

Though the company did not share the commission rate it charges partner hospitals, each consultation is said to be priced between INR 500 800 for patients, varying with cities and the type of hospitals. It also offers health-check packages and a monthly subscription called mfine ONE, which includes a free baseline health checkup and unlimited access to doctors.

Talking of the user demographic, Lawania said that 60%-65% users are from Tier 1 cities, while Tier 2 and Tier 3 make up for 30%-35% share of the companys user base. The company plans to expand into 40 cities in India over the next couple of years through hospital partnerships to bring more top doctors onto mfine. Also, mfine agreed to the possibility of entering the health insurance space by partnering with existing players in the insurance industry.

The Indian government has also been contributing towards improving access to healthcare growth with policies such as Pradhan Mantri Jan Arogya Yojana (PMJAY), which promised to provide health insurance worth INR 500K (roughly $7k) to over 100 Mn families annually.

Even after multiple attempts by the Indian government, the biggest gap in the Indian healthcare system is providing access to healthcare at the bottom of the pyramid. Most of the rural population in India find it hard to avail quality healthcare both because of geography and high healthcare costs.

While, mfines model of collaborating with hospitals does allow it to easily onboard doctors and patients, thanks to the high-ticket consultation fees at large hospitals, access to healthcare services is again limited to high income families only, who already have access to quality healthcare.

Contrary to mfines network of hospitals model is Medcords, which runs a network of local pharmacies which has helped the company to gain significant user base in the rural areas. Medcords told Inc42 in an earlier conversation that the startup chose not to partner with hospitals because that will potentially create a barrier for low income families. On the other hand, Practo tied up directly with medical practitioners and doctors to improve access.

Responding to this, Ashutosh said that the company is currently focussed on building a cloud network of quality private hospitals. However, it is also considering partnering with public hospitals at a later point in time, which would greatly help increase the affordability.

Ultimately that should be the end goal for most telemedicine startups that are hoping to improve access to healthcare. While in the urban context, partnering with private hospitals makes admissions and consultations easier for patients, its the rural population that is most in need of improved access to quality doctors and healthcare.

See the rest here:
Can mfines Hospital Network Bridge The Gaps In Indias Healthcare Delivery Systems - Inc42 Media

Making a Better Baby – Vision Insights and New Horizons

We always want to make things better. Recreating the world according to both our needs and our abilitiesstraightening the crooked branch, as it wereis our long-standing pattern, with a particular focus on life around us. Although weve known about the twisting branches of the DNA molecule at the heart of our tinkering for only 65 years or so, weve been breeding and crossbreeding for millennia in hopes of producing the biggest, the smallest, the tastiest or the hardiest.

Moving on to gene-splicing and now gene editing, we continue to reconfigure species to fit our desires. Whether dog, fish, tomato or soybean, many species and crops being marketed today are the product of our own design. In the future we may even endow our creations with genes and chromosomes created from scratch. Artificial intelligence can already dissect protein structure and function; from this may come the ability to design new proteins and then, taking one more hereditary step back, build their corresponding DNA sequences. Inserting these into embryonic cells would give the adult organisms new capacities and metabolic pathways never seen before.

How might we engineer our future children and, by extension, the human family as technology opens new doors to prune and straighten the next generation? Just imagine the possibilitiesand the pitfalls.

What would you be brave enough to do? Or not do?

Trees grow in all kinds of ways. Theyre not all perfectly straight. Not every limb is perfect.

Consider organ transplants. Soon someone will receive the first heart or kidney grown in a pig. In this case the pig genome will have been altered to silence or remove proteins that trigger the patients immune response, thus avoiding patient rejection.

But why not just make the pig more human? Human-animal hybrids are controversial but not out of the question. How about adding human stem cells to chimpanzee embryos? Michael Crichtons 2006 novel NeXT plays out just this kind of chimeric humanization-of-animals storyline.

Weve not yet grown a transgenic organism to term, but someday we likely will. The scientific impetus to use such an integrated platform to understand more about brain development, for example, may eventually overcome the ethical questions that so often arise in the surrounding moral ether.

What will actually happen next in human applications? In the 20th century, the focus was on controlling the outbreak and spread of infectious disease. The discovery of antibiotics and the development of vaccines, as well as access to clean water, were pivot points in human health.

As we moved into the 21st century, attention shifted to the human cell. The infectious-disease assault will continue, but what if we could edit disease out of the human genome altogether? This is such a fantastical thing to think about, Jennifer Doudna told Vision in 2016. You suddenly realize, Wow, we have a tool that in principle allows us to change human evolution. We can wipe out a mutation from the whole populationjust get rid of it.

Doudna, University of CaliforniaBerkeley professor of chemistry and molecular and cell biology, worked with Emmanuelle Charpentier (now at the Max Planck Unit for the Science of Pathogens in Berlin) to unlock the gene-editing potential of CRISPR-Cas9. When we came across this protein in the bacterial immune system, we werent looking for that, of course, Doudna explained; but once we understood how it worked we realized this would be an incredible tool for genome editing. Because we can program it with this little piece of RNA, we can make a break wherever we want to.

This means that scientists now have the molecular scissors and aiming system to make a specific edit among the 3 billion base pairs in our genome. Finding one particular letter in our DNA (the one incorrect letter on chromosome 11 that causes sickle-cell disease, for instance) is like finding one particular a in a stack of 900 Bibles; yet in any genomeanimal or plantCRISPR can find that letter and change it.

This has revolutionized biology, says Doudna.

Now we have a tool that allows rewriting of the genetic code, changing the DNA in cells. Thats a profound thing. It allows scientists to do things that in the past would have been really hard or impossible.

Gene editing is not limited to the scientific community. The low cost of CRISPR and the relative ease of self-training has opened its use to almost anyone. The 2019 Netflix documentary series Unnatural Selection reveals just how fast the democratization of molecular science is moving. We have no choice but to continue exploring the tree of knowledge, says one geneticist, but we always run the risk of discovering something that we cannot handle.

DNA code is not like computer software. A person is more than code, children more than the genes inherited from their parents. Still, genes are critically important because the code they carry determines physiological parameters that affect our health and who we are. They do limit us in one way or another. A tall person is not going to be a champion jockey; a claustrophobe wont be a good astronaut. We want to avoid disease, yet often the crooked branch is what gives us identity, individuality, even extraordinary gifts. The concern now is that definitions of disease and crooked might become quite malleable.

While it seems more practical and effective to invest in improving the social, cultural and mental environment that influences our well-being, weve emphasized the path to greater genetic influence. A decade before the advent of CRISPR, Gregory Stock recognized this fixation on the human genome: The possibility of altering the genes of our prospective children is not some isolated spinoff of molecular biology but an integral part of the advancing technologies that culminate a century of progress in the biological sciences (Redesigning Humans: Our Inevitable Genetic Future).

Thanks to gene-editing tools such as CRISPR, as well as an emerging kit of DNA-cutting proteins that are even more precise, the next generation of control has actually arrived. Its no longer a question of if or how; now the questions are Should we? and When? Will we be able to collectively determine when its safe to proceed? And who will determine which traits to change? Scientific groups have proposed moratoria on experimentation while they struggle for answers. In the meantime, gene editing is going on off-campus, unsupervised, in garages and kitchens.

In terms of therapeutic editing of patients cells (for example, immune cells removed from an adult and then returned to fight cancer) the cautionary lights have turned green, and many clinical trials are underway. But when to proceed with germ-line editing is trickier. Central to germ-line editing is the embryo; and in this case, creating the embryo is the job of in vitro fertilization (IVF).

Robert Edwards, the fertility pioneer who, with Patrick Steptoe, developed the first techniques of IVF, substantiated Stocks view of the progression. Writing in 2004 concerning the potential therapeutic power of embryonic stem cells, Edwards noted that development in several fields of biomedicine hinged on past success with human IVF. Producing stem cells through the creation of embryos, he said, had been among the primary intentions of introducing human IVF (another, of course, was to help infertile couples have babies).

Having access soon after egg and sperm unite, when there are very few cells to scissor, makes it possible to change the trajectory of both an individual life and a family line. Because every cell of the body carries the same DNA information as the first, a change in those first embryonic cells becomes a change everywhere. Its also possible to go back one more step: egg or sperm cells can be edited prior to fertilization.

Individuals created with any such alterations will pass them on to their children; by definition, these genetic modifications will become part of the germ line.

He Jiankui, formerly a biophysicist at Southern University of Science and Technology in Shenzhen, China, calls the embryo-editing procedure gene surgery. Gene surgery is another IVF advancement, He says. For a few children, early gene surgery may be the only viable way to heal an inheritable disease and prevent a lifetime of suffering.

In 2015 the first report of human-embryo gene modification was published. Using nonviable IVF embryos from fertility clinics, other Chinese scientists had tested the accuracy of CRISPR edits in humans. This advance came surprisingly soon on the heels of Doudna and Charpentiers discovery in 2012. According to Edward Lanphier, then president of Sangamo BioSciences, the ubiquitous access to and simplicity of creating CRISPRs creates opportunities for scientists in any part of the world to do any kind of experiments they want.

This early attempt at human germ-line modification prompted the first International Summit on Human Genome Editing (Washington DC, 2016). Following the summit, Doudna shared her concerns with Vision: I would like to see the community of peopleall of us who are now living in a world where we have this technology availablecoming together to understand it well enough that we can think as a society about how to employ it in ways that will be beneficial to people and will cause, hopefully, no harm. We need to maximize the good while minimizing the risks and the dangers.

At the time, Doudna was optimistic and generally confident that everyone could work together to move forward.

We want to proceed in a way that is respectful of human life and that is cautious, but also appreciates that there are patients desperately waiting for treatments. We need to be balancing the benefits and the risks.

By what rules or principles should this science advance? At the Second International Summit on Human Genome Editing (Hong Kong, 2018), He Jiankuialso known as JKplanned to present a series of principles that he and his collaborators believed would provide a solid humanitarian and ethical basis for moving forward with germ-line editing.

In the paper, Draft Ethical Principles for Therapeutic Assisted Reproductive Technologies, He and his colleagues proposed that a core set of fundamental human values be set by the medical and patient communities to advance a dialogue about the ethical use of ART [Assisted Reproductive Technology, including IVF] to help fertility-challenged couples conceive healthy children. Parameters for early-in-life genetic surgery would be brief and simple so as to be accessible to the public: Lawmakers in countries wishing to permit clinical trials and eventual regulatory submissions could build on these values to write cohesive rules that can still account for their countrys distinctive mix of religious beliefs, culture, and public-health challenges.

Initially the paper, published in The CRISPR Journal, seemed reasonable enough: Gene surgeries, including CRISPR gene editing and mitochondrial donation techniques, promise new therapeutic strategies during in vitro fertilization (IVF) to cure or prevent these diseases before a child can suffer. The authors went on to ask, What should be our proposed ethics and actual red lines?

Stanford neuroscientist William B. Hurlbut talks about his dealings with the Chinese researcher who created the worlds first gene-edited babies, and about the implications of that experiment.

They asserted, We have thought deeply about ethical foundations for regulation in discussions between researchers, patients and advocates, and ethicists both in China and abroad. One of those ethicists was William Hurlbut, who described his impressions of He in an interview with Vision: JK is a very nice person to talk with and is sincere in wanting to do good. ... He kept saying to me, We have to get this moving along, because the science is safe. He was convinced the science was safe.

JKs paper suggested five principles for determining whether germ-line editing should be approved in any given situation:

Its hard to disagree with any of these ideas.

We hold additional but less universal beliefs that further restrict the use of gene surgery, the authors noted, including the need to prioritize local population health needs and focus only on treating disease via prevalent, natural genetic variants.

As already noted, He Jiankui planned to present this material during the Hong Kong conference. In an e-mail to Vision, the moderator of the session, Robin Lovell-Badge (Francis Crick Institute, London), confirmed the timeline: Yes, JKs draft presentation did include a few slides on his view of the ethics of human germline genome editing. This was, according to Kevin Davies, the editor of The CRISPR Journal, always slated to be published around the time of the Summit meeting.

Just as one of the major problems with CRISPR editing is the danger of off-target misedits of the genome, Hes plan unraveled when it became known that he had already used CRISPR nine months earlier to edit and implant embryos. News of the birth of twins, dubbed Lulu and Nana, became public on the eve of the conference.

Lovell-Badge continued, I am fairly convinced that JK did not want the story of the babies to break until [a second] paper describing them was being published in a top journaland he appeared genuine when he apologized that the story broke early. Lovell-Badge has written an extensive account of behind-the-scenes meetings that took place at the time.

Was He Jiankui angling to create a kind of consensus supporting his ethics statements before his actions came to light? Had the scientific community supported his Draft Principles, it could arguably have helped both He and others justify what had been done. The principles, had they been sincere, might have paved the way for acceptance of germ-line editing.

According to Jon Cohen of Science, JK was also laying the groundwork for a kind of germ-line tourism business. Who knows how quickly we might have traveled that path had his timeline not tipped over? In failing to adhere to the cautionary principles that had existed by general agreement since 2016, he derailed any insight his Draft Principles might have provided; they have been dismissed as merely a bid to justify his own actions.

Citing Hes obvious conflict of interest, The CRISPR Journal retracted the paper. Its chief editor told Genetic Engineering and Biotechnology News: The authors intentionally hid from us the fact that they were conducting clinical research on germline editing, and that babies had been born. ... It is a mesmerizing gaze into the psyche of the authors before the news came out and how misguided they were.

He Jiankui has been martyred as a rogue scientist, but his venture into the gene pool has made the waters even more enticing. If any Rubicon to germ-line editing existed, it has now been crossed.

We have spent billions to unravel our biology, not out of idle curiosity, but in the hope of bettering our lives. We are not about to turn away from this.

Its clearly turned up the heat, Eric Juengst, director of the Center for Bioethics at the University of North Carolina, told Wired. Hes leapfrogged the safety research that everyone was calling for. The pressure is increased to actually get that research done.

According to Juengst, the article notes, a world with enhanced humans via gene-editing is an inevitability. People will have to learn to live in a world in which there are gene-edited fellow people among us, he said. And thats another focus that governments could take, to worry less about policing the science, and worry more about preparing society to live with this new kind of genetic diversity.

New regulations may create hard lines against germ-line modification, but if Lulu and Nana are normal and healthy (which has not yet been independently confirmed), desperate and/or curious parents will find an avenue to give it a try. In his book Designing Babies: How Technology Is Changing the Ways We Create Children, Robert Klitzman of the Columbia University Medical Center notes how difficult it will be to close the now-open door to germ-line editing.

Pointing to weak regulations and the free-market approach to ART that exists in many countries, including the United States, Klitzman has little confidence that attempts to regulate future implantation of edited embryos will be effective. Even the United Nations, with representatives from every country, has restricted powers, he notes. At some point, the transfer of gene-edited embryos into human wombs will probably be approved for use on an experimental or wider clinical basisonce its risks are better characterized, even though dangers will probably persist.

Klitzman continues, Many doctors and would-be parents prioritize patient autonomy over the rights of the future child, and minimize potential longer-term medical, psychological and social risks of ARTs. Given, in addition, the lucrative and competitive, profit-driven ART industry and its overall resistance to strong guidelines, numerous doctors might thus end up performing these procedures, with little regulatory or administrative hindrance (Klitzmans emphasis).

Assisted reproduction can do more than help infertile couples have a baby. It can help couples have the baby they want. So while we strive for health, there remains the question of whether we will objectify our children. Will we reduce them to products, fine-tuned, straightened and genetically honed to the parents recipe? In a consumer-conscious and market-driven world, a few may soon have both the economic and medical resources to purchase germ-line enhancements. One IVF parent explained his thinking to Klitzman: If youre paying to get a child, and this technology is there, why not use it? You go car shopping. You dont just want something that has four wheels. You might want a Mercedes. Thats why theres so many different kinds of cars. I dont see anything wrong with it.

Will we be brave enough to deny ourselves that future?

Eat of the forbidden fruit, God warns, and you shall surely die. Eat, promises the serpent, and you shall be like God. That temptationto be like Godis at the root of the ethical dilemmas posed by molecular biology.

In a video that was meant to coincide with the preplanned public announcement of Lulu and Nanas birth, He Jiankui made a poignant request. While there is collective skepticism about his motivations, his plea rings trueto remember that these babies are simply children for whom their parents believed they were doing the right thing. Did the parents understand the full implications of what he was asking them to undertake? Probably not, but desperate parents dont always see beyond their hope for a well child; theyre apt to grasp at any offer of help.

We hope that you have mercy for them, He said. Their parents dont want a designer babyjust a child who wont suffer from a disease which medicine can now prevent. Gene surgery is and should remain a technology for healing. [Enhancement] is not what a loving parent does. That should be banned. He concluded, I believe families need this technology and I am willing to take the criticism for them.

Was this bravery or bravado? A self-serving sales pitch or an earnest plea? In time well know whether Hes work was pioneeringor disastrous. In the meantime the research and the debates will continue.

The dark side of human nature is always with us. In the face of new trends in the world around, we need to think about how we, as individuals, will proceed.

At this stage, Doudna says, I support the plans of WHO and the National Academies to recommend strict regulation that precludes use [of germ-line editing] until scientific and technical questions are addressed and until ethical and societal matters are resolved. I prefer this to a moratorium which, to me, is of indefinite length and provides no pathway toward possible responsible use. Open discussion and transparency around this important topic should be encouraged, not suppressed.

Can the conflicts of interest that obscure clearheaded discussion be overcome? Who will lead that discussion? Self-interest is a powerful motivator. Researchers would need to hold themselves back, especially from exploring genetic enhancement. To expect such a thing, however, is to believe that all of us will be willing to step back from the threshold. It seems more likely that some will want to use these new tools to try to straighten things that need not be made straight.

If there were a fifth horseman of the Apocalypse, perhaps he would be genetically modified and his horse spurred forward by self-deception. Is it bravery to forge ahead into a new world of human genetic modification that will lead, almost inevitably, to enhancement, or is it wiser to step back, to resist that temptationto pull back on the reins and strive instead to be content with our variety, our limitations and our crooked branches? That is our collective challenge in this brave new world of making babies.

Follow this link:
Making a Better Baby - Vision Insights and New Horizons

The final frontier? Studying stem cells on the International Space Station – Scope

It's not often I get to write about astronauts and space travel. In fact, it's happened exactly... never. But now, thanks to a high-flying collaboration of Stanford researchers past and present, I get to write about something that's really out of this world.

Since 2006, iPS cells (short for induced pluripotent stem cells) have been at the forefront of groundbreaking research in biology and medicine. The cells' ability to become nearly any tissue in the body makes them an invaluable resource for physicians wishing to study the effect of drugs on specific, hard-to-obtain tissues or for researchers wanting to delve into the molecular missteps that lead to all manner of diseases.

Now iPS-derived human heart muscle cells called cardiomyocytes have found their way into space, as part of a study by cardiologist and stem cell researcher Joseph Wu, MD, PhD, graduate student Alexa Wnorowski and former Stanford graduate student Arun Sharma, PhD. With the help of NASA astronaut Kate Rubins, PhD, (also a former Stanford graduate student!), Wnorowski and Sharma studied the effect of the low gravity of the International Space Station on the heart cells' structure and function.

They published their findings today in Stem Cell Reports.

As Sharma, now a senior research fellow at Cedars-Sinai, explained in an email:

This project represented an opportunity for biomedical researchers to collaborate with astronauts and engineers in order to learn more about how a very unique environment, microgravity, affects the cells of the human heart.

Sharma, Wnorowski and Wu found that the cardiomyocytes cultured on the space station exhibited different patterns of gene expression than did their counterparts grown back here on Earth. They also displayed changes in the way they handled calcium -- an important regulator of contraction rate and strength.

Interestingly (and perhaps reassuringly for astronauts like Rubins), the cells appeared to return to normal when their five-and-a-half week jaunt into low Earth orbit ended.

"Working with the cells that launched to and returned from the International Space Station was an incredible opportunity," Wnorowski said. "Our study was the first conducted on the station that used human iPS technology, and demonstrated that it is possible to conduct long-term, human cell-based experiments in space."

All in all, the researchers were interested to see how nimbly the cells adjusted to their new, free floating life.

"We were surprised by how quickly human heart cells adapted to microgravity," Sharma said. "These results parallel known organ-level adaptations that happen to the heart during spaceflight."

Photos of Kate Rubins by NASA

Here is the original post:
The final frontier? Studying stem cells on the International Space Station - Scope

Space travel affects heart cells, but only temporarily – BBC Focus Magazine

The thought of spaceflight may make the heart skip a beat, but actually travelling beyond Earth could alter the organs cells.

With extended stays aboard the International Space Station (ISS) commonplace, and the likelihood of humans spending longer periods in space increasing, there is a need to better understand the effects of micro-gravity on cardiac function.

New research suggests heart muscle cells derived from stem cells have a remarkable ability to adapt to their environment during and after spaceflight.

Scientists examined cell-level cardiac function and gene expression in human heart cells cultured aboard the International Space Station for five-and-a-half weeks.They found that exposure to micro-gravity changed the expression of thousands of genes, but largely normal patterns reappeared within 10 days after returning to Earth.

Read more about the body in space:

Senior study author, Joseph Wu, of Stanford University School of Medicine, said: Our study is novel because it is the first to use human induced pluripotent stem cells to study the effects of spaceflight on human heart function.

Micro-gravity is an environment that is not very well understood, in terms of its overall effect on the human body, and studies like this could help shed light on how the cells of the body behave in space, especially as the world embarks on more and longer space missions such as going to the Moon and Mars.

Until now, most studies on how the heart reacts to micro-gravity have been conducted in either non-human models or at tissue, organ or systemic level.To address this, the beating cells were launched to the ISS aboard a SpaceX spacecraft as part of a commercial resupply service mission.Simultaneously, they were also cultured on Earth for comparison purposes.

When they returned to the planet, the cells showed normal structure and morphology.However, they did adapt by modifying their beating pattern and calcium recycling patterns.

Immunofluorescence imaging of the cells grown in micro-gravity aboard the International Space Station Joseph Wu lab, Stanford University School of Medicine/PA

Researchers sequenced the cells harvested at four-and-a-half weeks aboard the ISS, and 10 days after returning to Earth.Results showed that 2,635 genes were differentially expressed among flight, post-flight, and ground control samples.

Most notably, gene pathways related to mitochondrial function were expressed more in the space-flown cells, according to the research published in the Stem Cells Reports journal.

A comparison of the samples revealed the space cells adopted a unique gene expression pattern during spaceflight, which reverted to one that is similar to ground-side controls upon return to normal gravity.

Dr Wu added: Were surprised about how quickly human heart muscle cells are able to adapt to the environment in which they are placed, including micro-gravity.

These studies may provide insight into cellular mechanisms that could benefit astronaut health during long-duration spaceflight, or potentially lay the foundation for new insights into improving heart health on Earth.

Read more from the original source:
Space travel affects heart cells, but only temporarily - BBC Focus Magazine

Super-grafts That Could Treat Diabetes – Technology Networks

To save patients with a severe form of type 1 diabetes (characterized by the absence of functional insulin-producing cells), pancreatic cell transplantation is sometimes the last resort. The pancreas contains cell clusters called islets of Langerhans where cells that produce blood glucose regulating hormones are grouped together. However, the transplant process is long and complex: a significant part of the grafted cells die quickly without being able to engraft. By adding amniotic epithelial cells to these cell clusters, researchers at the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG), Switzerland, have succeeded in creating much more robust super-islets of Langerhans. Once transplanted, more of them engraft; they then start producing insulin much more rapidly. These results, to be discovered in Nature Communications, would not only improve the success of cell transplants, but also offer new perspectives for other types of transplants, including stem cell transplantation.

Today, islet transplantation is one of the last-chance options for patients with a particularly severe form of type 1 diabetes. The islets are removed from a donors pancreas, isolated and then re-injected into the patients liver. The procedure is well controlled about fifteen patients benefit from it every year in Switzerland but nevertheless complex, says Ekaterine Berishvili, a researcher in the Department of Surgery at UNIGE Faculty of Medicine, who led this work. Many of the islets die along the way. It often takes several donors to treat one person, whereas we are in desperate need of donors.

Placental cells to help grafts

To improve the success of islet transplantation and the survival of transplanted cells, researchers in Geneva have sought to create new, more robust islets that would withstand the stress of transplantation better than natural islets. To do this, they came up with the idea of adding amniotic epithelial cells, taken from the wall of the inner placenta membrane, to the pancreatic cells. These cells, very similar to stem cells, are already used in other therapies, such as corneal repair for example, says Thierry Berney, Professor in the Department of Surgery at UNIGE Faculty of Medicine and Head of HUG Transplant Division, who co-directed this work. In our case, we found that they can promote the function of pancreatic cells, which is to produce hormones according to fluctuations in sugar levels.

First step, in vitro: the addition of amniotic epithelial cells allowed the cell clusters to form regular spheres, indicating better intracellular communication and connectivity. Second step in vivo: the scientists transplanted their super-islets of Langerhans into diabetic mice, which quickly began to produce insulin. Even with few cell clusters, our super islets adapted very well to their new environment and quickly became vascularized, says Fanny Lebreton, a researcher in the Department of Surgery at UNIGE Faculty of Medicine and the first author of this work. A good vascularization is indeed the key element of any transplantation: it allows to supply the new organ with oxygen and nutrients and guarantees their survival. In addition, the artificial islets quickly began to produce insulin.

Improving oxygenation and protecting islets

Amniotic epithelial cells are thus essential to islet survival and seem to act on two vital elements: the lack of oxygen, which usually kills a large number of transplanted islets, and the modulation of the host immune system to limit the risk of rejection. In any transplant, the first step is to lower the recipients immunity to limit the risk of rejection, says Ekaterine Berishvili. Amniotic epithelial cells have the unique characteristic of protecting the foetus, which is also a non-self, from attacks by its mothers immune system. We believe that the same mechanism is at work to protect the grafts. The protective mechanism, observed here on cell transplants, could also take place in other types of transplants or even in xenotransplantation where non-human cells or organs are transplanted into humans.

These discoveries now need to be confirmed on human subjects. Since the use of amniotic epithelial cells is already common in other clinical settings without adverse side effects, this could be done relatively quickly. An important hope for all those awaiting a transplant.

Reference:Lebreton, F., Lavallard, V., Bellofatto, K., Bonnet, R., Wassmer, C. H., Perez, L., Berishvili, E. (2019). Insulin-producing organoids engineered from islet and amniotic epithelial cells to treat diabetes. Nature Communications, 10(1). https://doi.org/10.1038/s41467-019-12472-3

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more from the original source:
Super-grafts That Could Treat Diabetes - Technology Networks